US9458145, 1020-18

ID: ALA3926851

Chembl Id: CHEMBL3926851

Cas Number: 1637770-13-8

PubChem CID: 86301666

Max Phase: Preclinical

Molecular Formula: C25H22N4O

Molecular Weight: 394.48

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  Cc1ccc2ncccc2c1-c1cc(-c2c(C)noc2C)cc2nc(C3CC3)[nH]c12

Standard InChI:  InChI=1S/C25H22N4O/c1-13-6-9-20-18(5-4-10-26-20)22(13)19-11-17(23-14(2)29-30-15(23)3)12-21-24(19)28-25(27-21)16-7-8-16/h4-6,9-12,16H,7-8H2,1-3H3,(H,27,28)

Standard InChI Key:  KHQQNXFBTALTQF-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA3926851

   4-(2-cyclopropyl-7-(6-methylquinolin-5-yl)-1H-benzo[d]imidazol-5-yl)-3,5-dimethylisoxazole

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 394.48

Molecular Weight (Monoisotopic): 394.1794

AlogP: 6.24

#Rotatable Bonds: 3

Polar Surface Area: 67.60

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 11.67

CX Basic pKa: 5.80

CX LogP: 4.82

CX LogD: 4.81

Aromatic Rings: 5

Heavy Atoms: 30

QED Weighted: 0.39

Np Likeness Score: -0.84

References

1.  (2016)  Benzimidazole derivatives as bromodomain inhibitors, 

2. Sperandio D, Aktoudianakis V, Babaoglu K, Chen X, Elbel K, Chin G, Corkey B, Du J, Jiang B, Kobayashi T, Mackman R, Martinez R, Yang H, Zablocki J, Kusam S, Jordan K, Webb H, Bates JG, Lad L, Mish M, Niedziela-Majka A, Metobo S, Sapre A, Hung M, Jin D, Fung W, Kan E, Eisenberg G, Larson N, Newby ZER, Lansdon E, Tay C, Neve RM, Shevick SL, Breckenridge DG..  (2019)  Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.,  27  (3): [PMID:30606676] [10.1016/j.bmc.2018.11.020]

Source

Source(2):

• Scientific Literature
• BindingDB Database